1 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | 2件: 6 6, 162 |
2 | A single blood sample for HLA typing | - | - | - | - | 3件: 35 35, 38, 162 |
3 | AC-203 1% Topical Ointment | - | - | - | - | 1件: 162 162 |
4 | AKST4290 | - | - | - | - | 2件: 6 6, 162 |
5 | ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED | - | - | - | - | 5件: 36 36, 38, 53, 96, 162 |
6 | Allogenic mesenchymal stem cell isolated from adipose tissue | - | - | - | - | 3件: 38 38, 96, 162 |
7 | Apremilast | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 7件: 46 46, 50, 56, 97, 107, 162, 271 |
8 | ARAVA | 1件: Leflunomide Leflunomide | 1件: D00749
D00749
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 3件: 46 46, 53, 162 |
9 | Avdoralimab | 1件: Avdoralimab Avdoralimab | - | - | - | 1件: 162 162 |
10 | Avdoralimab (IPH5401) | 1件: Avdoralimab Avdoralimab | - | - | - | 1件: 162 162 |
11 | Azathioprine | 1件: Azathioprine Azathioprine | 1件: D00238
D00238
| - | - | 21件: 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 |
12 | Azathioprine or Mycophenolate mofetil | 3件: Azathioprine Azathioprine, Mycophenolate mofetil, Mycophenolic acid | 3件: D00238
D00238
,
D00752
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 |
13 | Baricitinib | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 13件: 2 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 |
14 | Baricitinib 2 MG [Olumiant] | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 162 162 |
15 | Benralizumab | 1件: Benralizumab Benralizumab | 1件: D09874
D09874
| 1件: IL5RA IL5RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 5件: 44 44, 45, 98, 162, 299 |
16 | Bertilimumab | - | - | - | - | 2件: 97 97, 162 |
17 | BIV009 | - | - | - | - | 2件: 61 61, 162 |
18 | Blood test | - | - | - | - | 6件: 36 36, 51, 107, 113, 162, 299 |
19 | CC | - | - | - | - | 13件: 28 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271 |
20 | CC-10004 | - | - | - | - | 5件: 46 46, 56, 97, 162, 271 |
21 | Cellcept® in autoimmune bullous dermatoses | - | - | - | - | 2件: 35 35, 162 |
22 | Clobetasol | 1件: Clobetasol Clobetasol | 1件: D07715
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 4件: 39 39, 46, 51, 162 |
23 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: D07715
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
24 | Clobetasol Propionate | 2件: Clobetasol Clobetasol, Clobetasol propionate | 2件: D01272
D01272
,
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 46 46, 162 |
25 | Clobetasol propionate + Methotrexate | 3件: Clobetasol Clobetasol, Clobetasol propionate, Methotrexate | 3件: D00142
D00142
,
D01272
,
D07715
| 3件: DHFR DHFR, DHFR2, NR3C1 💬 | 6件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate 💬 | 1件: 162 162 |
26 | Clobetasol propionate alone | 2件: Clobetasol Clobetasol, Clobetasol propionate | 2件: D01272
D01272
,
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
27 | Clobetasol Propionate cream treatment | 2件: Clobetasol Clobetasol, Clobetasol propionate | 2件: D01272
D01272
,
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
28 | Cortancyl | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 35 35, 41, 162 |
29 | CORTANCYL 20 mg | 1件: Prednisone acetate Prednisone acetate | 1件: D08416
D08416
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 |
30 | Cultivated oral mucosal epithelial sheet transplantation | - | - | - | - | 2件: 38 38, 162 |
31 | Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 44件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 |
32 | Cyclophosphamide 50Mg Oral Tablet | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 162 162 |
33 | Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 37件: 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
34 | Dapsone | 1件: Dapsone Dapsone | 1件: D00592
D00592
| - | - | 5件: 35 35, 42, 60, 84, 162 |
35 | Data report | - | - | - | - | 1件: 162 162 |
36 | Dermoval | - | - | - | - | 2件: 35 35, 162 |
37 | Dexamethasone | 1件: Dexamethasone Dexamethasone | 1件: D00292
D00292
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 22件: 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
38 | Dexamethasone 0.5mg/5ml solution | 1件: Dexamethasone Dexamethasone | 1件: D00292
D00292
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 |
39 | Dexamethasone 0.5mg/5ml solution in Mucolox™ | 1件: Dexamethasone Dexamethasone | 1件: D00292
D00292
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 |
40 | DF2156A | - | - | - | - | 1件: 162 162 |
41 | Double Dose | - | - | - | - | 2件: 38 38, 162 |
42 | Doxycycline | 1件: Doxycycline Doxycycline | 2件: D00307
D00307
,
D07876
| - | - | 17件: 13 13, 23, 28, 34, 46, 84, 85, 89, 96, 97, 158, 161, 162, 167, 227, 280, 299 |
43 | Dupilumab | 1件: Dupilumab Dupilumab | 1件: D10354
D10354
| 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 5件: 51 51, 97, 98, 160, 162 |
44 | Dupixent | 1件: Dupilumab Dupilumab | 1件: D10354
D10354
| 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 3件: 98 98, 160, 162 |
45 | EFGARTIGIMOD ALFA | 1件: Efgartigimod alfa Efgartigimod alfa | 1件: D11876
D11876
| 1件: FCGRT FCGRT 💬 | - | 6件: 11 11, 14, 35, 53, 63, 162 |
46 | Efgartigimod PH20 SC | - | - | - | - | 5件: 11 11, 14, 35, 63, 162 |
47 | Fasenra | 1件: Benralizumab Benralizumab | 1件: D09874
D09874
| 1件: IL5RA IL5RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 5件: 44 44, 45, 98, 162, 299 |
48 | Gold | 1件: Gold Gold | - | - | - | 43件: 2 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318 |
49 | Halometasone | 1件: Halometasone Halometasone | 1件: D07202
D07202
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
50 | Imatinib | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
51 | Infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 26件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
52 | INTERLEUKIN-2 | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 10件: 2 2, 35, 49, 50, 53, 55, 65, 96, 97, 162 |
53 | IPH5401 | - | - | - | - | 1件: 162 162 |
54 | Ixekizumab | 1件: Ixekizumab Ixekizumab | 1件: D10071
D10071
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 8件: 36 36, 37, 46, 107, 160, 162, 269, 271 |
55 | Ladarixin | 1件: Ladarixin Ladarixin | - | - | - | 1件: 162 162 |
56 | Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP | 5件: Dapsone Dapsone, Mycophenolate mofetil, Mycophenolic acid, Prednisolone, Triamcinolone | 5件: D00385
D00385
,
D00472
,
D00592
,
D00752
,
D05096
| 3件: IMPDH1 IMPDH1, IMPDH2, NR3C1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 |
57 | Leflunomide | 1件: Leflunomide Leflunomide | 1件: D00749
D00749
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 12件: 11 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300 |
58 | MabThera | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 22件: 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 |
59 | Mabthéra | - | - | - | - | 2件: 35 35, 162 |
60 | Mathéra | - | - | - | - | 2件: 35 35, 162 |
61 | MEDI-563 | - | - | - | - | 5件: 44 44, 45, 98, 162, 299 |
62 | Medrone | - | - | - | - | 4件: 46 46, 51, 83, 162 |
63 | MEPOLIZUMAB | 1件: Mepolizumab Mepolizumab | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 4件: 44 44, 45, 98, 162 |
64 | Mepolizumab (a-IL-5 antibody) | 1件: Mepolizumab Mepolizumab | 1件: D04923
D04923
| 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 162 162 |
65 | Methotrexate | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
66 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 46件: 2 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
67 | Minocycline | 1件: Minocycline Minocycline | 1件: D05045
D05045
| - | - | 13件: 2 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
68 | MMF | - | - | - | - | 16件: 13 13, 35, 40, 46, 49, 50, 51, 60, 65, 66, 107, 162, 222, 224, 226, 299 |
69 | Mometasone | 1件: Mometasone Mometasone | 1件: D08227
D08227
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 98 98, 162 |
70 | MOMETASONE FUROATE | 2件: Mometasone Mometasone, Mometasone furoate | 2件: D00690
D00690
,
D08227
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 98 98, 162 |
71 | MTX | - | - | - | - | 14件: 13 13, 35, 40, 46, 49, 50, 51, 60, 84, 96, 97, 107, 162, 271 |
72 | Mycophenolate | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
73 | Mycophenolate mofetil | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: D00752
D00752
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
74 | Myfortic | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 5件: 49 49, 66, 162, 222, 228 |
75 | Myfortic 180 mg | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 |
76 | Myfortic 180 mg Filmtabletten | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 |
77 | Nicotinamide | 1件: Nicotinamide Nicotinamide | 1件: D00036
D00036
| - | - | 8件: 2 2, 6, 18, 49, 97, 107, 162, 191 |
78 | NNC0215-0384 | - | - | - | - | 2件: 46 46, 162 |
79 | NOMACOPAN | 1件: Nomacopan Nomacopan | 1件: D11473
D11473
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 162 162 |
80 | Nomacopan (rVA576) | 1件: Nomacopan Nomacopan | 1件: D11473
D11473
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 162 162 |
81 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 |
82 | Olive | 1件: Olea europaea leaf Olea europaea leaf | - | - | - | 5件: 13 13, 35, 49, 53, 162 |
83 | Olive oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 5件: 13 13, 35, 49, 53, 162 |
84 | OMALIZUMAB | 1件: Omalizumab Omalizumab | 1件: D05251
D05251
| 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 7件: 46 46, 53, 65, 98, 162, 226, 299 |
85 | Oral corticosteroids (OCS) | - | - | - | - | 1件: 162 162 |
86 | Otezla | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 3件: 56 56, 107, 162 |
87 | Ozonated olive oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 2件: 35 35, 162 |
88 | PREDNISOLONE | 1件: Prednisolone Prednisolone | 1件: D00472
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 42件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
89 | Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 45件: 2 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
90 | QGE031 | - | - | - | - | 1件: 162 162 |
91 | Restasis | - | - | - | - | 2件: 53 53, 162 |
92 | Riboflavin | 1件: Riboflavin Riboflavin | 1件: D00050
D00050
| - | - | 7件: 38 38, 46, 96, 97, 162, 168, 265 |
93 | RITUXIMAB | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 48件: 11 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
94 | Rituximab 1g IV | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 162 162 |
95 | Rituximab combined with Omalizumab | 2件: Omalizumab Omalizumab, Rituximab | 2件: D02994
D02994
,
D05251
| 2件: FCER1A FCER1A, MS4A1 💬 | 5件: Asthma Asthma, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 162 162 |
96 | RVA576 | - | - | - | - | 3件: 62 62, 109, 162 |
97 | Simvastatin | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 21件: 6 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 |
98 | Simvastatin-ratiopharm | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 162 162 |
99 | Simvastatin-ratiopharm® | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 162 162 |
100 | Single Dose | - | - | - | - | 2件: 38 38, 162 |
101 | Solu-Medrone | - | - | - | - | 3件: 51 51, 83, 162 |
102 | Tildrakizumab | 1件: Tildrakizumab Tildrakizumab | 1件: D10400
D10400
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 162 162, 271 |
103 | Tildrakizumab Prefilled Syringe | 1件: Tildrakizumab Tildrakizumab | 1件: D10400
D10400
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 162 162 |
104 | Topical garamycin cream | - | - | - | - | 2件: 35 35, 162 |
105 | Topical infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 38 38, 39, 162 |
106 | Treatment systemic therapy (prednisone) | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
107 | Treatment with systemic therapy (doxycycline) | 1件: Doxycycline Doxycycline | 2件: D00307
D00307
,
D07876
| - | - | 1件: 162 162 |
108 | Treatment with systemic therapy (methotrexate) | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 162 162 |
109 | Treatment with systemic therapy (prednisone) | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
110 | Treatment with topical superpotent corticosteroid therapy | - | - | - | - | 1件: 162 162 |
111 | Triamcinolone | 1件: Triamcinolone Triamcinolone | 1件: D00385
D00385
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 11件: 35 35, 46, 53, 56, 70, 90, 96, 107, 162, 226, 298 |
112 | Tripterygium | 1件: Tripterygium wilfordii whole Tripterygium wilfordii whole | - | - | - | 8件: 46 46, 66, 67, 96, 162, 222, 224, 271 |
113 | Ustekinumab | 1件: Ustekinumab Ustekinumab | 1件: D09214
D09214
| 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 16件: 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |